1Epoch Pharmaceuticals, Inc., Bothell, WA 98021, USA.
Researchers developed selective binding complementary oligonucleotides (SBC ODNs) by modifying DNA bases. These novel SBC ODNs bind specifically to complementary DNA or RNA, offering new tools for molecular biology applications.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: